Meaningful Response to TILs in NSCLC

Area of Science:

• Oncology
• Immunotherapy

Background:

• Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality.
• Standard treatments, including PD-1/PD-L1 checkpoint inhibitors, are ineffective for a significant proportion of patients.
• Novel therapeutic strategies are urgently needed for refractory NSCLC.

Discussion:

• Tumor-infiltrating lymphocyte (TIL) therapy, such as LN-145, represents a personalized immunotherapy approach.
• Preliminary findings indicate LN-145's potential efficacy in heavily pretreated NSCLC patients.
• The therapy involves ex vivo expansion of tumor-reactive lymphocytes for reinfusion.

Key Insights:

• LN-145 demonstrated an overall response rate (ORR) of 21.4% in patients with advanced NSCLC.
• Responses were observed in patients whose disease progressed despite prior PD-1 or PD-L1 inhibitor therapy.
• The median duration of response was not reached, suggesting durable responses.

Outlook:

• Further clinical trials are warranted to confirm these preliminary findings.
• LN-145 could offer a valuable treatment alternative for patients with limited therapeutic options.
• Personalized TIL therapy may expand the landscape of effective NSCLC treatments.